topic

685 A first-in-human Phase 1/2 clinical trial of SIRPα^low activated macrophages (SIRPant-M) for the treatment of R/R-NHL
Koby Kidder, Rita N Barcia, Stephen Fogelson, Candida Fratazzi, Nathanael McCurley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A778; DOI: 10.1136/jitc-2023-SITC2023.0685
686 Targeted immunotherapy and checkpoint blockade in children, adolescents, and young adults with lymphoma: RADICAL hodgkin cohort
Kayleigh Klose, Jessica C Hochberg, Jaclyn Baso, Ana C Xavier, Anthony N Audino, Matthew Barth, Rodney Miles, Samir Kahwash, Stephan D Voss, Suzanne Braniecki, Chitti Moorthy, Saro Armenian, Matthew Ehrhardt, Megan S Lim, Lauren Harrison, Arvind Budhram, Ariel Stonberg, Stanton Goldman, Mitchell S Cairo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A779; DOI: 10.1136/jitc-2023-SITC2023.0686
688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib
Klaus H Metzeler, Uwe Platzbecker, Eric S Winer, Amit Verma, Daniel J DeAngelo, Mariano Severgnini, Chia-Cheng Li, Gaurav S Choudhary, Wanying Zhao, Maureen Lane, Alyssa Masciarelli, Reinhard Von Roemeling, Dora Ferrari, Cole Gallagher, Samantha Carlisle, David Nickle, Guillermo Garcia-Manero

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A780; DOI: 10.1136/jitc-2023-SITC2023.0688
689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
Deeksha Vishwamitra, Sheri Skerget, M Damiette Smit, Lien Vandenberk, Kalpana Bakshi, Sangmin Lee, Bhagirathbhai Dholaria, María-Victoria Mateos, Ajai Chari, Paula Rodriguez-Otero, Nizar Bahlis, Niels WCJ van de Donk, Raluca Verona

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A781; DOI: 10.1136/jitc-2023-SITC2023.0689
690 High safety and efficacy of CRISPR-Based non-viral PD1 locus specific Integrated Anti-CD19 CAR-T cells (BRL-201) in treating relapsed or refractory non-Hodgkin’s lymphoma: first-in-human phase I study
Biao Zheng, YongXian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A782; DOI: 10.1136/jitc-2023-SITC2023.0690
691 First-in-human trial of novel HBsAg-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma
Xueshuai Wan, Wei Wu, Yunpeng Liu, Shunda Du, Wei Li, Dongmei Quan, Xiaorui Wang, Ulrike Protzer, Yuhong Zhou, Xiujuan Qu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A783; DOI: 10.1136/jitc-2023-SITC2023.0691
692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
Meredith Pelster, Antonio Jimeno, Trisha Wise-Draper, Jong Chul Park, Victoria Villaflor, Kerry J Rodabaugh, Wade T Iams, Julia Jennings, Melinda Morrison, Nathan Miselis, Scott Loughhead, Howard Bernstein, Marshelle S Warren, Justin C Moser, Michael S Gordon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A784; DOI: 10.1136/jitc-2023-SITC2023.0692
693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors
Victoria Villaflor, Rajwanth Veluswamy, Emese Zsiros, Anthony F Shields, Shivani Joshi, Julia Jennings, Nathan Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Richard T Maziarz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A785; DOI: 10.1136/jitc-2023-SITC2023.0693
694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)⁺/CD141(BDCA-3)⁺ myeloid dendritic cells in solid tumors
Manon Vounckx, Jens Tijtgat, Iris Dirven, Frederik Vandenbroucke, Steven Raemaeckers, Bart Ilsen, Selma Ben Mustapha, Jens Van Loon, Latoya Stevens, Xenia Geeraerts, Ivan Van Riet, Ines Dufait, Sandra Tuyaerts, Lore Decoster, Mark De Ridder, Bart Neyns

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A786; DOI: 10.1136/jitc-2023-SITC2023.0694
695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
Parneet Cheema, Sylvia Hartl, Marianna Koczywas, Maximilian Hochmair, Frances A Shepherd, Quincy Chu, Giuseppe Galletti, Mark Gustavson, Sonia Iyer, J Carl Barrett, Brent Evans, Rakesh Kumar, Jan Cosaert, Keunchil Park, John V Heymach

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A787; DOI: 10.1136/jitc-2023-SITC2023.0695

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages